AJMC January 3, 2022
Andrew Mulcahy, PhD, MPP, Christine Buttorff, PhD, Kenneth Finegold, PhD, Zeid El-Kilani, MPP, Jon F. Oliver, PhD, Stephen Murphy, PhD, Amber Jessup, PhD

Projected savings from biosimilars from 2021 to 2025 were $38.4 billion vs conditions as of quarter 4 of 2020 and were driven by new biosimilar entry. Savings were $124.5 billion under an upper-bound scenario.

ABSTRACT

Objectives: Biologics account for an increasing share of US prescription drug spending. Biosimilars could lower biologic prices through competition, but barriers to increasing both supply and uptake remain. We projected US biosimilar savings from 2021 to 2025 under different scenarios.

Study Design: We projected US spending on biologics over a 5-year period under 3 scenarios: (1) a baseline scenario holding quarter 4 (Q4) of 2020 market conditions constant; (2) under main assumptions allowing for biosimilar market growth and entry; and (3) an upper-bound scenario assuming...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Pharma / Biotech
Related Articles:
GLP1 Drugs Not Tied to Pregnancy Loss, Birth Defects
FDA advisers to weigh first psychedelic therapy in early June
Verve moves forward with backup base editing therapy
STAT+: Young boy dies in trial for Pfizer Duchenne gene therapy
Healthy Returns: Eli Lilly, Novo Nordisk make progress toward boosting weight loss drug supply

Share This Article